AI Article Synopsis
- The rise of treatment resistance to common older treatments for parasitic skin conditions like scabies and head lice highlights the importance of IVM as a safe and effective alternative.
- IVM may also have potential benefits in treating inflammatory skin conditions, such as papulopustular rosacea, where certain skin mites (demodex) might contribute to the issue.
Article Abstract
Ivermectin (IVM) is a broad-spectrum anti-parasitic drug with significant anti-inflammatory properties. The emergence of treatment resistance to lindane, permethrin, and possibly malathion complicates the global strategy for management of common parasitic skin diseases such as scabies and head lice. In this regard. IVM has been safely and effectively used in the treatment of these common human infestations. In addition, IVM may be useful in inflammatory cutaneous disorders such as papulopustular rosacea where demodex may play a role in pathogenesis. Herein, we review the current applications of topical IVM in dermatology.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Topical Formulation Containing Ferment for Managing Barrier Damage After Mild-Moderate Skin Disruption from Cosmetic Dermatologic Procedures.
J Clin Aesthet Dermatol
January 2025
Dr. Saliou is with The Estée Lauder Companies in Melville, New York.
Objective: The primary objective of these studies was to evaluate the potential of a serum containing Macrocystis pyrifera ferment (MPF-Serum) to both strengthen the barrier of intact skin and enhance barrier recovery after a non-ablative laser procedure or glycolic acid chemical peel.
Methods: Two whole-face clinical trials and three split-face, randomized, controlled clinical trials were conducted in women aged 31 to 65 years. The effect of MPF-Serum on barrier integrity and strength was assessed by transepidermal water loss measurement before and after controlled tape-stripping experiments and in-clinic 70% glycolic acid peel and non-ablative laser procedures.
Topical Carboxytherapy for Skin Rejuvenation.
J Clin Aesthet Dermatol
January 2025
Drs. Simmons-O'Brien and Orlinsky are with Simmons-O'Brien & Orlinsky, LLC, in Towson, Maryland.
Driven by public demand, new safe and effective approaches for achieving dermal rejuvenation are continuously being developed. Recently, there has been growing interest and advances in carbon dioxide therapy, or carboxytherapy. Based on the Bohr effect, carboxytherapy enhances the release of O from the blood into the surrounding tissues in response to increased blood CO.
View Article and Find Full Text PDFReal-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series.
J Clin Aesthet Dermatol
January 2025
Ms. Pomaville is with Forefront Dermatology in Berwyn, Illinois; the Marquette University College of Health Sciences, PA Studies Program in Milwaukee, Wisconsin; and the University of Dubuque, MSPAS Program, in Dubuque, Iowa.
Seborrheic dermatitis (SD) is an inflammatory skin disease with multifactorial etiology, involving genetic and environmental factors. Many conventional therapies for SD (ie, topical antifungals, topical corticosteroids) are associated with incomplete efficacy, frequent and sometimes rapid disease recurrence, and restrictions on duration of therapy and anatomic sites of application. This may be because they cannot target multiple disease processes and/or are limited by safety considerations.
View Article and Find Full Text PDFA Prospective, Open-Label, Randomized, Comparative, Investigator-Initiated Study to Evaluate the Safety and Effectiveness of Autologous Growth Factor Concentrate Using the Healrex Therapy Kit With Standard Wound Care in Lower-Extremity Diabetic Ulcer.
Cureus
December 2024
Business Development Hospitals, Wockhardt Hospitals Ltd., Mumbai, IND.
Background and objectives The persistent nature of diabetic foot ulcers (DFUs) is mainly attributable to compromised wound healing mechanisms, which are aggravated due to poor blood flow, neuropathy, and infection. Growth factors have become essential agents in the treatment of DFUs, serving as primary mediators that enhance wound healing through the stimulation of cell proliferation, migration, and angiogenesis. This prospective open-label, randomised, comparative, multi-centre, investigator-initiated study compared the safety and effectiveness of adjuvant therapy with topical application of autologous growth factor concentrate (AGFC) using the Healrex therapy kit (Wockhardt, India) versus standard of care (SoC) in DFUs.
View Article and Find Full Text PDFSelective Tissue Penetration of the Corneal Layers of Cyclosporin 2% Associated with Miglyol in Rabbits.
J Ocul Pharmacol Ther
January 2025
Ophtalmology Department, Rouen University Hospital, Rouen, France.
Cyclosporin A (CsA) is a drug used to prevent immune rejection in corneal transplantation. Most grafts performed today are endothelial grafts which are complicated with poor penetration of CsA into the endothelium due to its hydrophobicity. To improve CsA penetration into the corneal a new ocular formulation of CsA 2% with Miglyol was developed and is commercially available.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!